These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
104 related articles for article (PubMed ID: 21092676)
1. [Inhibition of cell growth by rapamycin through targeting mammalian target of rapamycin signaling pathway in nasopharyngeal carcinoma]. Li YL; Zhang X; Liu Y; Li SS; Xie L; Zhang N; Liu XB; Tian YQ Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2010 Sep; 45(9):765-8. PubMed ID: 21092676 [TBL] [Abstract][Full Text] [Related]
2. Rapamycin provides a therapeutic option through inhibition of mTOR signaling in chronic myelogenous leukemia. Li J; Xue L; Hao H; Han Y; Yang J; Luo J Oncol Rep; 2012 Feb; 27(2):461-6. PubMed ID: 21993902 [TBL] [Abstract][Full Text] [Related]
3. Combined targeting of the VEGFr/EGFr and the mammalian target of rapamycin (mTOR) signaling pathway delays cell cycle progression and alters adhesion behavior of prostate carcinoma cells. Wedel S; Hudak L; Seibel JM; Juengel E; Tsaur I; Haferkamp A; Blaheta RA Cancer Lett; 2011 Feb; 301(1):17-28. PubMed ID: 21122981 [TBL] [Abstract][Full Text] [Related]
4. Antiproliferative effect of rapamycin on human T-cell leukemia cell line Jurkat by cell cycle arrest and telomerase inhibition. Zhao YM; Zhou Q; Xu Y; Lai XY; Huang H Acta Pharmacol Sin; 2008 Apr; 29(4):481-8. PubMed ID: 18358095 [TBL] [Abstract][Full Text] [Related]
5. The mTOR inhibitor RAD001 sensitizes tumor cells to the cytotoxic effect of carboplatin in breast cancer in vitro. Liu H; Zang C; Schefe JH; Schwarzlose-Schwarck S; Regierer AC; Elstner E; Schulz CO; Scholz C; Possinger K; Eucker J Anticancer Res; 2011 Sep; 31(9):2713-22. PubMed ID: 21868512 [TBL] [Abstract][Full Text] [Related]
6. Sirolimus inhibits human pancreatic carcinoma cell proliferation by a mechanism linked to the targeting of mTOR/HIF-1 alpha/VEGF signaling. Wang Y; Zhao Q; Ma S; Yang F; Gong Y; Ke C IUBMB Life; 2007 Nov; 59(11):717-21. PubMed ID: 17968710 [TBL] [Abstract][Full Text] [Related]
7. Rapamycin induces apoptosis of JN-DSRCT-1 cells by increasing the Bax : Bcl-xL ratio through concurrent mechanisms dependent and independent of its mTOR inhibitory activity. Tirado OM; Mateo-Lozano S; Notario V Oncogene; 2005 May; 24(20):3348-57. PubMed ID: 15782132 [TBL] [Abstract][Full Text] [Related]
8. Rapamycin causes poorly reversible inhibition of mTOR and induces p53-independent apoptosis in human rhabdomyosarcoma cells. Hosoi H; Dilling MB; Shikata T; Liu LN; Shu L; Ashmun RA; Germain GS; Abraham RT; Houghton PJ Cancer Res; 1999 Feb; 59(4):886-94. PubMed ID: 10029080 [TBL] [Abstract][Full Text] [Related]
9. [Inhibitory effect and significance of rapamycin on the mammalian target of rapamycin signaling pathway in osteosarcoma stem cells and osteosarcoma cells]. Liu PY; Zhang WB; Wang J; Shen YH; Wei YY Zhonghua Zhong Liu Za Zhi; 2013 Mar; 35(3):175-80. PubMed ID: 23879996 [TBL] [Abstract][Full Text] [Related]
10. Activation of mammalian target of rapamycin signaling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphoma. Peponi E; Drakos E; Reyes G; Leventaki V; Rassidakis GZ; Medeiros LJ Am J Pathol; 2006 Dec; 169(6):2171-80. PubMed ID: 17148679 [TBL] [Abstract][Full Text] [Related]
11. Combination mammalian target of rapamycin inhibitor rapamycin and HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin has synergistic activity in multiple myeloma. Francis LK; Alsayed Y; Leleu X; Jia X; Singha UK; Anderson J; Timm M; Ngo H; Lu G; Huston A; Ehrlich LA; Dimmock E; Lentzsch S; Hideshima T; Roodman GD; Anderson KC; Ghobrial IM Clin Cancer Res; 2006 Nov; 12(22):6826-35. PubMed ID: 17121904 [TBL] [Abstract][Full Text] [Related]
12. Mammalian target of rapamycin inhibitors rapamycin and RAD001 (everolimus) induce anti-proliferative effects in GH-secreting pituitary tumor cells in vitro. Gorshtein A; Rubinfeld H; Kendler E; Theodoropoulou M; Cerovac V; Stalla GK; Cohen ZR; Hadani M; Shimon I Endocr Relat Cancer; 2009 Sep; 16(3):1017-27. PubMed ID: 19509067 [TBL] [Abstract][Full Text] [Related]
13. Effects of a JAK inhibitor, AG490, on proliferation and apoptosis of human nasopharyngeal carcinoma cell line CNE-2Z. Wu MH; Chen XY; Cai KR Ai Zheng; 2009 Jan; 28(1):24-8. PubMed ID: 19448411 [TBL] [Abstract][Full Text] [Related]
14. [Can defective TGF-Beta signaling be an Achilles heel in human cancer?]. Foster DA; Gadir N Ai Zheng; 2008 Aug; 27(8):882-4. PubMed ID: 18710627 [TBL] [Abstract][Full Text] [Related]
15. Cutaneous T-cell lymphoma cells are sensitive to rapamycin. Kremer M; Sliva K; Klemke CD; Schnierle BS Exp Dermatol; 2010 Sep; 19(9):800-5. PubMed ID: 20629739 [TBL] [Abstract][Full Text] [Related]
16. Activation of peroxisome proliferator-activated receptor gamma inhibits cell growth via apoptosis and arrest of the cell cycle in human colorectal cancer. Lin MS; Chen WC; Bai X; Wang YD J Dig Dis; 2007 May; 8(2):82-8. PubMed ID: 17532820 [TBL] [Abstract][Full Text] [Related]
17. [In vitro inhibitory effect of dibenzoxanthene CY-B12 on proliferation of tumor cell lines and its possible mechanisms]. Pu XX; Jiang GF; Chen Y; Xu ZL; Xian LJ Ai Zheng; 2005 Dec; 24(12):1442-7. PubMed ID: 16351789 [TBL] [Abstract][Full Text] [Related]
18. Inhibition of the mammalian target of rapamycin (mTOR) by rapamycin increases chemosensitivity of CaSki cells to paclitaxel. Faried LS; Faried A; Kanuma T; Nakazato T; Tamura T; Kuwano H; Minegishi T Eur J Cancer; 2006 May; 42(7):934-47. PubMed ID: 16540312 [TBL] [Abstract][Full Text] [Related]
19. Inhibitory effect of rapamycin on corneal neovascularization in vitro and in vivo. Kwon YS; Hong HS; Kim JC; Shin JS; Son Y Invest Ophthalmol Vis Sci; 2005 Feb; 46(2):454-60. PubMed ID: 15671269 [TBL] [Abstract][Full Text] [Related]
20. Mammalian target of rapamycin is required for thrombopoietin-induced proliferation of megakaryocyte progenitors. Drayer AL; Olthof SG; Vellenga E Stem Cells; 2006 Jan; 24(1):105-14. PubMed ID: 16123382 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]